FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1017-1018 March 28, 2002 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Herrington, D. M. PubMed Citation

For many years, the conventional wisdom, backed by observational epidemiologic studies, has held that "replacement" of estrogen after menopause would restore the relative protection from cardiovascular disease enjoyed by premenopausal women as compared with men of a similar age. This view was bolstered by a number of apparently beneficial effects of oral estrogen therapy on risk factors for cardiovascular disease, most notably reductions in the level of low-density lipoprotein (LDL) cholesterol and increases in the level of high-density lipoprotein (HDL) cholesterol. Recent clinical trials, however, have failed to support a benefit of hormone-replacement therapy in terms of clinical events¹ and . . . [Full Text of this Article]

References

Related Letters:

Estrogen-Receptor Polymorphism and Hormone-Replacement Therapy
Garrido J. A., Grant E. C.G., Herrington D. M., Reboussin D. M.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:762-763, Sep 5, 2002. Correspondence

This article has been cited by other articles:

• Eriksson, A.-L., Skrtic, S., Niklason, A., Hulten, L. M., Wiklund, O., Hedner, T., Ohlsson, C. (2004). Association between the low activity genotype of catechol-O-methyltransferase and myocardial infarction in a hypertensive population. Eur Heart J 25: 386-391 [Abstract] [Full Text]  
• Ferrero, V., Ribichini, F., Matullo, G., Guarrera, S., Carturan, S., Vado, A., Vassanelli, C., Piazza, A., Uslenghi, E., Wijns, W. (2003). Estrogen Receptor-{alpha} Polymorphisms and Angiographic Outcome After Coronary Artery Stenting. Arterioscler. Thromb. Vasc. Bio. 23: 2223-2228 [Abstract] [Full Text]  
• Garrido, J. A., Grant, E. C.G., Herrington, D. M., Reboussin, D. M. (2002). Estrogen-Receptor Polymorphism and Hormone-Replacement Therapy. NEJM 347: 762-763 [Full Text]  
• (2002). Tailoring Drug Treatment to Genetics: An Evolving Estrogen Story?. JWatch General 2002: 5-5 [Full Text]